Placebo matching mepolizumab

DRUG3 trials

Sponsors

GlaxoSmithKline

Conditions

Dermatitis, AtopicEosinophilic Granulomatosis With PolyangiitisHypereosinophilic Syndrome

Phase 2

Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis

TerminatedNCT03055195

GlaxoSmithKlineDermatitis, Atopic

Start: 2017-03-21End: 2017-12-06Updated: 2020-02-25

Phase 3

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

CompletedNCT02836496

GlaxoSmithKlineHypereosinophilic Syndrome

Start: 2017-03-07End: 2019-08-08Updated: 2020-02-21

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

Active, not recruitingNCT05263934

GlaxoSmithKlineEosinophilic Granulomatosis With Polyangiitis

Start: 2022-07-14End: 2026-10-27Updated: 2026-07-08

Related Papers

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine2023-03-299 citations

Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome

Frontiers in Immunology2022-08-266 citations

Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.

2022-05-1218 citations

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Frontiers in Immunology2022-04-137 citations